Please login to the form below

Not currently logged in
Email:
Password:

Aimmune Therapeutics

This page shows the latest Aimmune Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Nestlé and Seres announce new partnership for C.diff microbiome therapeutic

Nestlé and Seres announce new partnership for C.diff microbiome therapeutic

difficile infection,” added Greg Behar, CEO of Nestlé Health Science. In September 2020, Nestlé furthered its push into pharma with the acquisition of allergy specialist Aimmune Therapeutics in a deal worth ... Aimmune’s Palforzia became the first

Latest news

  • EU authorises Aimmune’s peanut allergy treatment Palforzia EU authorises Aimmune’s peanut allergy treatment Palforzia

    Approval in the EU comes nine months after US authorisation. Aimmune Therapeutics’ Palforzia has received approval from the European Commission (EC) for the treatment of a peanut allergy. ... Aimmune’s potential rival, DBV Technologies, has not had

  • Nestlé is set to acquire Aimmune in deal worth $2.6bn Nestlé is set to acquire Aimmune in deal worth $2.6bn

    Aimmune’s Palforzia therapy is the only FDA-approved peanut allergy drug. Nestlé has announced plans to acquire allergy specialist Aimmune Therapeutics in a deal worth $2.6bn, six months after ... Aimmune’s launch of Palforzia has been hampered by

  • FDA knocks back DBV’s peanut allergy therapy once again FDA knocks back DBV’s peanut allergy therapy once again

    Drug loses further ground to Aimmune's Palforzia. DBV Technologies’ struggle to get its peanut allergy therapy approved looks set to drag on, after the US Food and Drug Administration (FDA) ... Every month of delay gives Aimmune more time to extend its

  • Aimmune’s Palforzia is first peanut allergy drug cleared in US Aimmune’s Palforzia is first peanut allergy drug cleared in US

    Aimmune has also filed for approval in Europe, with a verdict due later this year. ... Analysts at GlobalData have suggested the market for peanut allergy products in eight major world markets could be worth $4.5bn in 2027, with Aimmune claiming a

  • DBV refiles peanut allergy immunotherapy in the US DBV refiles peanut allergy immunotherapy in the US

    four to 11 years, as it tries to catch up with a rival programme from US company Aimmune Therapeutics that is already under FDA review. ... GlobalData has predicted that Aimmune’s drug will have two-thirds of the market in 2027, with DBV’s drug

More from news
Approximately 5 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Integrating patient reported outcomes into clinical trials Integrating patient reported outcomes into clinical trials

    Aimmune Therapeutics prepared for commercialisation by using two PRO scales to show the effect of its peanut allergy drug on people’s emotions and social lives. ... Cara Therapeutics put two questionnaires about itching at the centre of its phase 3

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    Forecast sales for Skyrizi in 2023 are $1.74bn. AR-101 from Aimmune Therapeutics addresses peanut allergy. ... However, Aimmune reported in February 2019 that the FDA had initially determined that the drug, as an allergenic extract, was exempt from the

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Now a US biotech company, Aimmune, looks set to bring the first treatment to market by the end of this year. ... Aimmune Therapeutics submitted the drug to the FDA on 21 December.

  • Deal Watch November 2016 Deal Watch November 2016

    licence, collaboration. 167. Aimmune Therapeutics/ Nestlé Health Science. CODIT (Characterised Oral Desensitisation ImmunoTherapy), for treating life-threatening food. ... acquisition - company. 80. Arsia Therapeutics/ Eagle Pharmaceuticals. viscosity

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite

Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...